EDP-420: Ketolide antibiotic

Drugs of the Future

Volumn 31, Issue 6, 2006, Pages 479-483

  Revill, P ^a   Bolos J ^a   Serradell, N ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

9 (ACETYLAMINO) 9 DEOXO 3 DES(HEXOPYRANOSYLOXY) 3 OXO 6 O, 11 O [2 [6 (1H PYRAZOL 1 YL)PYRIDIN 3 YLMETHOXYIMINO]PROPYLENE]ERYTHROMYCIN A; 9 ACETYLIMINO 3 DEHEXAPYRANOSYLOXY 9 DEOXO 3 OXO 6 O,11 O [2 [6 (1 PYRAZOLYL) 3 PYRIDINYLMETHOXYIMINO]PROPYLENE]ERYTHROMYCIN; AZITHROMYCIN; CEFTRIAXONE; CETHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN DERIVATIVE; ISONIAZID; KETOLIDE; LEVOFLOXACIN; MACROLIDE; MEFLOQUINE; PENICILLIN G; QUINOLONE; TELITHROMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ATYPICAL MYCOBACTERIOSIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LUNG INFECTION; MAXIMUM ALLOWABLE CONCENTRATION; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; REVIEW; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; STRUCTURE ACTIVITY RELATION;

EID: 33748795576     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2006.031.06.997162     Document Type: Review

References (20)

1. Or, Y.S., Wang, Y., Kim, H. et al. (Enanta Pharmaceuticals, Inc.). 6-17 Bicyclic ketolide derivs. EP 1506214, JP 2005530803, US 2005037982, US 6878691, WO 2003097659.
2. Scorneaux, B., Arya, A., Polemeropoulos, A. et al. In vitro and in vivo evaluation of EP-13420: A novel ketolide highly active against resistant pathogens and having exceptional pharmacokinetic properties in the dog. 43rd Intersci Conf Antimicrob Agents Chemother (ICAAC) (Sept 14-17, Chicago) 2003, Abst F-1191.
3. Vazquez, D. The macrolide antibiotics. In: Antibiotics III. Mechanism of Action of Antimicrobial and Antitumor Agents. Corcoran, J.W., Hahn, F.E. (Eds.). Springer-Verlag, New York, 1975, 459-79.
4. Berisio, R., Harms, J., Schluenzen, F., Zarivach, R., Hansen, H.A., Fucini, P., Yonath, A. Structural insights into the antibiotic action of telithromycin against resistant mutants. J Bacteriol 2003, 185: 4276-9.
5. Brown, S.D., Farrell, D.J., Morrissey, I. Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study. J Clin Microbiol 2004, 42(11): 4980-7.
6. Zhong, P., Shortridge, V. The emerging new generation of antibiotic ketolides. Curr Drug Targets Infect Disord 2001, 1: 125-31.
7. Schlunzen, F., Harms, J., Franceschi, F. et al. Structural basis for the antibiotic activity of ketolides and azalides. Structure (Cambridge) 2003, 11: 329-38.
8. Maki, H., Fujimura, T., Yamano, Y., Shimada, J., Kuwahara, S. S-013420, a new bridged bicyclic ketolide: I. In vitro antibacterial activity. 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst F-2029.
9. Young, L.S., Bermudez, L.E., Inderlied, C.B. et al. In vitro and in vivo activity of 6-11 bridged bicyclic ketolides (including EP-13420) against the M. avium complex (MAC). 44th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Oct 30-Nov 2, Washington, D.C.) 2004, Abst F-1408.
10. Chee, C., Kolonoski, P., Wu, M., Bermudez, L.E., Young, L.S., Wang, G., Phan, L.T. Post-antibiotic effect of a novel bridged ketolide, EDP-420 (EP-013420), against Mycobacterium avium complex (MAC). 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst F-2031.
11. Bermudez, L.E., McNab, M.D., Young, L.S., Wang, G., Phan, L.T. EDP-420 (EP-013420), a bridged ketolide, inhibits formation of Mycobacterium avium (MAC) biofilm and the entry into human bronchiolar cells. 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst F-2032.
12. Cynamon, M.H., Sklaney, M., Wang, G., Phan, L.T. In vitro and in vivo activities of several bridged bicyclic ketolides against M. tuberculosis. 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst F-1470.
13. Tsuji, M., Miwa, H., Takema, M., Kanaoka, E., Yoshikawa, T., Shimada, J., Kuwahara, S. S-013420, a new bridged bicyclic ketolide: II. In vivo activity against experimental animal infection models. 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst S-2035.
14. Kolonoski, P., Chee, C., Baimukanova, G., Bermudez, L.E., Young, L.S., Wang, G., Phan, L.T. A novel bridged ketolide, EDP-420 (EP-013420) does not select for resistance after 8-12 weeks therapy of disseminated Mycobacterium avium complex (MAC) infection in C57 beige mice. 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst F-2033.
15. Cottagnoud, M., Acosta, F., Stucki, A. et al. EDP-420 is efficacious in experimental meningitis caused by penicillin and quinolone-resistant pneumococci. 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst F-2034.
16. Maglio, D., Sun, H., Patel, T. et al. Pharmacodynamics of a new bridged bicyclic ketolide (BBK) EP-13420 in a murine S. pneumoniae (SPN) pneumonia model. 44th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Oct 30-Nov 2, Washington, D.C.) 2004, Abst F-1407.
17. Jiang, L., Drusano, G., Nguyen, P. et al. Pharmacokinetics (PK), lung tissue distribution and epithelial lining fluid (ELF) penetration of EDP-420 in uninfected rats. 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) (Dec 16-19, Washington, D.C.) 2005, Abst A-26.
18. Comparative study of EDP-420 versus another antibiotic in the treatment of community acquired pneumonia (NCT00270517). ClinicalTrials.gov Web site 2006.
19. EDP-420 begins North American phase II trial for CAP. DailyDrugNews.com 2006, January 23.
20. Enanta receives milestone for initiation of phase II trials in Japan for EDP-420. DailyDrugNews.com 2005, December 23.